ArticleDiscover oncology2026
A manganese metabolism-related gene signature for prognosis prediction and immune microenvironment description of glioblastoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM), as a high-grade glioma, has high invasiveness and poor clinical prognosis. Manganese is an important trace element, has been proven to be closely related to tumor treatment and tumor immunity. It is necessary to explore the correlation between manganese metabolism-related genes and GBM.
methodsWe downloaded RNA gene expression data and clinical data of GBM patients from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas database (CGGA) databases. Build the signature using data from TCGA-GBM and independently validate it using data from CGGA-GBM. Next, we will use a nomogram to predict the clinical prognosis of GBM patients. Finally, we analyzed the relationship between the prognostic model and immune microenvironment through CIBERSORT.
resultsA total of 495 manganese metabolism-related differentially expressed genes were obtained for the establishment of a subsequent signature in the TCGA-GBM cohort. The following seven genes (PLAT, TIMP1, FN1, CTSB, SCG5, GALNT6 and AMPH) were used to establish the signature and independently validated using the CGGA-GBM dataset. Research has confirmed that the predictive ability of this signature exceeds other clinical features, and the receiver operating characteristic curve has a high area under the curve.
conclusionsWe constructed and validated a novel gene signature related to manganese metabolism in GBM patients. This gene signature not only reliably predicts the clinical outcomes of GBM patients but also has the potential to guide the provision of new treatment options for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.